79. Homozygous familial hypercholesterolemia
128 clinical trials,   105 drugs   (DrugBank: 29 drugs),   8 drug target genes,   15 drug target pathways

Searched query = "Homozygous familial hypercholesterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-003449-15-GB
(EUCTR)
12/07/200709/03/2007A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia SubjectsA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects - RADICHOL I Reduction of low density lipoprotein C (LDL-C) in Homozygous Familial Hypercholesterolemia (HoFH)
MedDRA version: 9.1;Level: LLT;Classification code 10057080;Term: Homozygous familial hypercholesterolemia
Genzyme Europe B.V.NULLNot Recruiting Female: yes
Male: yes
50Phase 3United Kingdom
2NCT00607373
(ClinicalTrials.gov)
July 200722/1/2008Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial HypercholesterolemiaA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen as Add-on Therapy in Homozygous Familial Hypercholesterolemia SubjectsLipid Metabolism, Inborn Errors;Hypercholesterolemia, Autosomal Dominant;Hyperlipidemias;Metabolic Diseases;Hyperlipoproteinemia Type II;Metabolism, Inborn Errors;Genetic Diseases, Inborn;Infant, Newborn, Diseases;Metabolic Disorder;Congenital Abnormalities;Hypercholesterolemia;Hyperlipoproteinemias;Dyslipidemias;Lipid Metabolism DisordersDrug: mipomersen;Drug: PlaceboKastle Therapeutics, LLCIonis Pharmaceuticals, Inc.Completed12 YearsN/AAll51Phase 3United States;Brazil;Canada;Singapore;South Africa;Taiwan;United Kingdom;Netherlands
3NCT00280995
(ClinicalTrials.gov)
January 200620/1/2006Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering TherapyA Phase 2, Open-Label, Dose Escalation Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia SubjectsHypercholesterolemia, FamilialDrug: ISIS 301012Kastle Therapeutics, LLCIonis Pharmaceuticals, Inc.Completed18 YearsN/ABoth12Phase 2United States;Netherlands